This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
In development [GID-MT539] Expected publication date: 01 September 2020
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 (CLN2) in children
Evidence-based recommendations on voretigene neparvovec (Luxturna) for RPE65-mediated inherited retinal dystrophies (confirmed biallelic RPE65 gene mutations)
Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy
Evidence-based recommendations on culizumab (Soliris) for treating atypical haemolytic uraemic syndrome (aHUS)
Evidence-based recommendations on inotersen (Tegsedi) for stage 1 and stage 2 polyneuropathy in adults with hereditary transthyretin amyloidosis
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia (XLH) in children and young people
Evidence-based recommendation on Strimvelis for adenosine deaminase deficiency–severe combined immunodeficiency (ADA–SCID)
Evidence-based recommendations on asfotase alfa (Strensiq) for treating paediatric-onset hypophosphatasia in adults and children
Evidence-based recommendations on eliglustat (Cerdelga) for treating type 1 Gaucher disease in adults
Evidence-based recommendations on migalastat (Galafold) for treating Fabry disease in people over 16
Evidence-based recommendations on ataluren (Translarna) for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene..
Evidence-based recommendations on elosulfase alfa (Vimizim) for treating mucopolysaccharidosis type IVa (MPS IVA)
In development [GID-MT530] Expected publication date: 01 June 2020
In development [GID-HST10009] Expected publication date: TBC
Proposed [GID-HST10020] Expected publication date: TBC
Proposed [GID-HST10022] Expected publication date: TBC
Proposed [GID-HST10023] Expected publication date: TBC
In development [GID-HST10010] Expected publication date: TBC
In development [GID-HST10026] Expected publication date: 08 September 2020
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
Proposed [GID-HST10019] Expected publication date: TBC
Proposed [GID-HST10028] Expected publication date: TBC
In development [GID-HST10027] Expected publication date: 11 November 2020
In development [GID-HST10015] Expected publication date: 03 June 2020
In development [GID-HST10011] Expected publication date: 13 January 2021
In development [GID-HST10017] Expected publication date: TBC
We are listening to your views on this highly specialised technology. Comments close 27 January 2020.
Evidence-based recommendations on gammaCore for cluster headache
Evidence-based decisions on Endocuff Vision for assisting visualisation during colonoscopy
Evidence-based recommendations on Curos for preventing infections when using needleless connectors
Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions
Evidence-based recommendations on UrgoStart for treating diabetic foot ulcers and leg ulcers
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain
Evidence-based recommendations on Mepilex Border Heel and Sacrum dressings for preventing pressure ulcers
Evidence-based recommendations on iFuse titanium implant joint fusion system for treating chronic sacroiliac (SI) joint pain (lower back pain)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy (nerve damage) by detecting inadequate sweat production
Evidence-based recommendations on Thopaz+ for people who need chest drainage after a pulmonary resection or because of a collapsed lung
Evidence-based recommendations on the Peristeen transanal irrigation system for people with bowel dysfunction
Evidence-based recommendations on Memokath-051 stent for treating ureteric obstruction
Evidence-based recommendations on SecurAcath for securing percutaneous catheters (central venous catheters/CVCs)
Evidence-based recommendations on ENDURALIFE-powered cardiac resynchronisation therapy-defibrillator (CRT-D) devices for treating heart failure
Evidence-based recommendations on HeartFlow FFRCT for estimating fractional flow reserve from coronary CT angiography
Evidence-based recommendations on HumiGard for preventing inadvertent perioperative hypothermia in patients having abdominal surgery
Evidence-based recommendations on the XprESS multi-sinus dilation system for treating chronic sinusitis after medical treatment has failed